Vincent, Rich, and Brianne discuss a study estimating the fraction of symptoms and severe disease after SARS- CoV-2 infection, cellular immune responses without seroconversion during interfamilial infections, and answer listener email.

Daniel Griffin provides a clinical update on COVID-19, including analysis of the dexamethasone trial, and then we discuss two Ebolavirus outbreaks in DRC, clinical and virological aspects of asymptomatic SARS-CoV-2 infections, age-dependent effects on transmission, and answer listener email.

Vincent and Rich discuss the SARS-CoV-2 D614G amino acid change in the spike glyprotein, duration of infectious virus shedding from patients, virus transmission among hamsters infected in the laboratory, and tackle listener email.

Daniel Griffin provides a clinical update on COVID-19, then Ralph Baric joins TWiV to discuss SARS-CoV-2 transmission, vaccines, diagnostic tests, and a new animal model from his laboratory that does not use transgenic mice.

Peter Daszak joins TWiV to explain the work of EcoHealth Alliance in surveillance of bats in China for SARS-related coronaviruses to provide the information needed to prevent future pandemics, and why NIH recently withdrew financial support for their work.

Daniel Griffin provides a clinical update on COVID-19, then we review an Ad5 vectored SARS-CoV-2 vaccine, reports on remdesivir and hydroxychloroquine, a drug repurposing study, why some patients infect many others, reducing viral transmission, and much more, including listener email.

From the Nipah Virus International Conference in Singapore, Vincent speaks with meeting participants about the history of the first Nipah virus outbreak, lessons learned from Hendra virus, surveillance of bats for viruses, and the development of a vaccine.

Daniel Griffin provides a clinical update on COVID-19, then we review TETRIS by Paterson NJ, modeling the effects of intervention in the US on cases and deaths, mixing PCR and serology data, and much more, including listener email.